On September 8, 2024, the Ministry of Commerce, the National Health Commission and the National Medical Products Administration jointly issued the Notice on Expanding the Pilot Program for Opening Up in the Medical Field, announcing that, effective immediately, foreign-invested enterprises may engage in the development and application of human stem cell, gene diagnosis and therapy technologies in the Beijing Pilot Free Trade Zone, the Shanghai Pilot Free Trade Zone, the Guangdong Pilot Free Trade Zone, and the Hainan Free Trade Port.